Iovance Biotherapeutics Inc’s recently made public that its Chief Commercial Officer Kirby Daniel Gordon acquired Company’s shares for reported $55200.0 on Jun 05 ’25. In the deal valued at $1.84 per share,30,000 shares were bought. As a result of this transaction, Kirby Daniel Gordon now holds 30,000 shares worth roughly $80400.0.
Then, Puri Raj K. bought 5,600 shares, generating $9,743 in total proceeds. Upon buying the shares at $1.74, the Chief Regulatory Officer now owns 206,852 shares.
Before that, Vogt Frederick G bought 25,000 shares. Iovance Biotherapeutics Inc shares valued at $42,250 were divested by the Interim CEO & General Counsel at a price of $1.69 per share. As a result of the transaction, Vogt Frederick G now holds 374,646 shares, worth roughly $1.0 million.
Goldman downgraded its Iovance Biotherapeutics Inc [IOVA] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid May from “a Buy” to “a Neutral”. Truist also remained covering IOVA and has decreased its forecast on May 12, 2025 with a “Hold” recommendation from previously “Buy” rating. Citizens JMP revised its rating on May 09, 2025. It rated IOVA as “a Mkt perform” which previously was an “a Mkt outperform”.
Price Performance Review of IOVA
On Friday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock jump 4.28% to $2.68. Over the last five days, the stock has lost -14.38%. Iovance Biotherapeutics Inc shares have fallen nearly -70.09% since the year began. Nevertheless, the stocks have fallen -63.78% over the past one year. While a 52-week high of $12.51 was reached on 01/02/25, a 52-week low of $1.64 was recorded on 05/19/25.
Levels Of Support And Resistance For IOVA Stock
The 24-hour chart illustrates a support level at 2.52, which if violated will result in even more drops to 2.35. On the upside, there is a resistance level at 2.78. A further resistance level may holdings at 2.87.
How much short interest is there in Iovance Biotherapeutics Inc?
A steep rise in short interest was recorded in Iovance Biotherapeutics Inc stocks on 2025-07-15, growing by 7.67 million shares to a total of 98.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 90.96 million shares. There was a rise of 7.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 24, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $17 price target.
